Cargando…
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for th...
Autores principales: | Oliveira, Lilliana, Cohen, Russell D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063115/ https://www.ncbi.nlm.nih.gov/pubmed/21448448 http://dx.doi.org/10.2147/DDDT.S5392 |
Ejemplares similares
-
Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007) -
Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009) -
The role of mesalamine in the treatment of ulcerative colitis
por: Karagozian, Raffi, et al.
Publicado: (2007) -
2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial
por: Suzuki, Yasuo, et al.
Publicado: (2017) -
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
por: Doherty, Glen A, et al.
Publicado: (2009)